Expression of molecules of HIPPO/LATS pathway in chronic neoplasms myeloproliferative

• Grant number: 14/04234-9
• Support Opportunities: Scholarships in Brazil - Doctorate
• Effective date (Start): December 01, 2014
• Effective date (End): August 31, 2018
• Field of knowledge: Health Sciences - Medicine
• Acordo de Cooperação: Coordination of Improvement of Higher Education Personnel (CAPES)
• Principal Investigator: Fabíola Attié de Castro
• Grantee: Maira da Costa Cacemiro
• Host Institution: Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Associated scholarship(s): 16/03265-3 - Study of CALR del52 and ins5 knock-in mouse models and comparison to the JAK2V617F knock-in mouse model, BE.EP.DR

Abstract

Chronic myeloproliferative neoplasms (CMPN) are haematological disease characterized by the increase of mature hematopoietic cells of one or more of the myeloid series (granulocyte, erythrocyte , megakaryocyte or mast cells) proliferation. Among the CMPN we will investigate the polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (MF).CMPN may present the JAK2V617F mutation which occurs in 95 % of PV patients and 50% of ET and MF patients. The JAK2V617F mutation constitutively active STAT3 transducer protein, which is related to apoptosis resistance and myeloproliferation in these diseases. Although all the molecular knowledge about CMPN pathogenesis, these diseases do not have a efficient therapy. Thus, more studies to better understand their pathophysiology and description of new therapeutic targets, as the molecules via the HIPPO / LATS are needed.This study will investigate the relationship between apoptosis impairment and the Hippo-LATS pathway deregulation in PV, ET and MF patients. The gene expression of Hippo-LATS pathway members will be quantify in CMPN patients leukocytes, Hel.92.1.7 and SET 2 cell lines treated or untreated with JAK2 inhibitors. (AU)

Scientific publications

(4)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

CACEMIRO, MAIRA DA COSTA; BERZOTI-COELHO, MARIA GABRIELA; COMINAL, JUCARA GASTALDI; BURIN, SANDRA MARA; DE CASTRO, FABIOLA ATTIE. Hippo pathway deregulation: implications in the pathogenesis of haematological malignancies. Journal of Clinical Pathology, v. 70, n. 1, p. 9-14, JAN 2017. (15/25637-7, 15/23555-3, 14/04234-9)

MAIRA DA COSTA CACEMIRO; JUÇARA GASTALDI COMINAL; RAQUEL TOGNON; NATALIA DE SOUZA NUNES; BELINDA PINTO SIMÕES; LORENA LÔBO DE FIGUEIREDO-PONTES; LUIZ FERNANDO BAZZO CATTO; FABÍOLA TRAINA; ELIZABETH XISTO SOUTO; FABIANA ALBANI ZAMBUZI; et al. Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation. Hematology, Transfusion and Cell Therapy, v. 40, n. 2, p. 120-131, 2018-06-00. (16/03265-3, 15/21237-4, 14/04234-9)

BENATI, ROGERIO BODINI; COSTA, TASSIA RAFAELA; CACEMIRO, MAIRA DA COSTA; SAMPAIO, SUELY VILELA; DE CASTRO, FABIOLA ATTIE; BURIN, SANDRA MARA. Cytotoxic and pro-apoptotic action of MjTX-I, a phospholipase A2 isolated from Bothrops moojeni snake venom, towards leukemic cells. Journal of Venomous Animals and Toxins including Tropical Diseases, v. 24, DEC 20 2018. (15/00740-0, 15/25637-7, 11/23236-4, 14/04234-9)

CACEMIRO, MAIRA DA COSTA; COMINAL, JUCARA GASTALDI; PEREIRA, LUIZ MIGUEL; BERZOTI-COELHO, MARIA GABRIELA; BERBEL, GIOVANA MICHELASSI; BARONI, LUCIANA; MALTA, TATHIANE; TOGNON, RAQUEL; NUNES, NATALIA DE SOUZA; SOUTO, ELIZABETH XISTO; et al. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms. MEDICAL ONCOLOGY, v. 39, n. 5, p. 11-pg., 2022-05-01. (13/08135-2, 14/50947-7, 15/23555-3, 18/19714-7, 15/21866-1, 14/04234-9)

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

CACEMIRO, Maira da Costa. Expression of Hippo pathway molecules in myeloproliferative neoplasms. 2018. Doctoral Thesis - Universidade de São Paulo (USP). Faculdade de Ciências Farmacêuticas de Ribeirão Preto (PCARP/BC) Ribeirão Preto.